Nicole Keith

Investor Relations Contact at JUNO THERAPEUTICS INC

Health Technology

Profile

Nicole Keith is currently working as an Investor Relations Contact at Juno Therapeutics, Inc. since 2015.
She is also currently working as an Investor Relations & Media professional at Sana Biotechnology, Inc. Ms. Keith previously worked as the Head-Investor Relations at Onyx Pharmaceuticals, Inc. from 2012 to 2013.

Nicole Keith active positions

Companies	Position	Start
JUNO THERAPEUTICS INC	Investor Relations Contact	2015-06-30
SANA BIOTECHNOLOGY, INC.	Public Communications Contact	-

All active positions of Nicole Keith

Former positions of Nicole Keith

Companies	Position	End
Onyx Pharmaceuticals, Inc. Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA.	Public Communications Contact	2013-11-30

See the detail of Nicole Keith's experience

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Nicole Keith's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	1
SANA BIOTECHNOLOGY, INC.	Health Technology

Private companies	2
Onyx Pharmaceuticals, Inc. Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA.	Health Technology
Juno Therapeutics, Inc. Juno Therapeutics, Inc. BiotechnologyHealth Technology Juno Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of innovative cellular immunotherapy for the treatment of cancer. It offers platforms which includes chimeric antigen receptors and T-cell receptors. The company was founded by Hans Edgar Bishop, Lawrence Corey, Richard D. Klausner, Stan Riddell, Isabelle Riviere, and Robert Taylor Nelsen on August 5, 2013 and is headquartered in Seattle, WA.	Health Technology